6.39% Less Aclaris Therapeutics Inc (NASDAQ:ACRS) Shorted Shares

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Corporate Logo

Change of 6.39% for Aclaris Therapeutics Inc (NASDAQ:ACRS)’s shorted shares was showed. In December was announced ACRS’s total 4.34M shorted shares by FINRA. The 4.64 million previous shares are down with 6.39%. Aclaris Therapeutics Inc (NASDAQ:ACRS) has 339,400 shares average volume. It’ll cost 13 days for ACRS to restore its former position. Float short on Aclaris Therapeutics Inc is 17.84%.

The stock decreased 3.84% or $0.33 during the last trading session, reaching $8.26.Currently Aclaris Therapeutics, Inc. is downtrending after 42.52% change in last December 8, 2017. ACRS has also 286,837 shares volume. ACRS underperformed by 58.14% the S&P 500.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology.The company has $338.13 million market cap. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor.Currently it has negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

For more Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news announced briefly go to: Globenewswire.com, Nasdaq.com, Globenewswire.com, Globenewswire.com or Benzinga.com. The titles are as follows: “FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia Areata – GlobeNewswire” announced on July 09, 2018, “Aclaris Therapeutics Launches Direct-to-Consumer Campaign for ESKATA┬« (hydrogen peroxide) Topical Solution 40%, (w/w) – Nasdaq” on October 01, 2018, “Aclaris Therapeutics Announces Issuance of Additional Orange Book Listable Patent Covering ESKATA – GlobeNewswire” with a publish date: May 30, 2018, “Aclaris Therapeutics to Present at the 2018 American Hair Research Summit – GlobeNewswire” and the last “25 Stocks Moving In Thursday’s Pre-Market Session – Benzinga” with publication date: October 18, 2018.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.